Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms (MPNs), which he recently covered in a presentation during the Texas Virtual MPN Workshop.
In the MPN field, no targeted agents were available prior to the development of the JAK inhibitor ruxolitinib (Jakafi). Later, other JAK inhibitors were developed and are considered to be efficacious for the treatment of some patients. Pemmaraju notes that not all patients respond to JAK inhibitors, not all patients are eligible to receive a JAK inhibitor, and some patients are intolerant. Overall, JAK inhibitors do not appear to be curative in MPNs, leaving allogeneic stem cell transplant as the only curative treatment in the space, says Pemmaraju.
The addition of novel agents to a ruxolitinib regiment is the new strategy for patients who cannot derive benefit from ruxolitinib alone. Pemmaraju says, novel combinations are already being explored for the treatment of acute and chronic leukemias, and now is the time to try this strategy in MPNs.
<< View more resources and information regarding myeloproliferative neoplasms
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More